Summary
How RHHBY maps according to Revere
| Sector Level | Count |
|---|---|
Industries
|
2 |
Sectors
|
7 |
Subsectors
|
30 |
Product/Service Groups
|
227 |
Specific product example for RHHBY
| Product Hierarchy |
|---|
Healthcare
|
Biopharmaceuticals
|
Allergies
|
Phase I/Phase II Clinical Stage Products
|
Company Highlights:
Market Cap.
|
145,117.557 |
Current Shares Outstnd.
|
3,450.3 |
| Contact Name | Dr. Karl Mahler |
| Contact Phone | (61)6881111 |
| City, State | Basel |
| Dividends Per Common Share | 6.80 |
| Dividend Yield | 4.38 |
IH % Shares Outst.
|
0.45% |
| Number of Employees | 80,653 |
| Revenue Per Employee | 664,913.5 |
| Book Value Per Share | 14.02 |
| 5 Year CAGR in Revenues % | 5.98 |
| 5 Year CAGR in Earnings % | 7.94 |
Asset Turnover
|
0.34 |
| Fiscal Year End | 12/31/2012 |
| Next Reporting Period | Mar, 2012 |
Business Description:
Chart:
| Last Price | 42.06 |
| Price Chg. | 0.00 |
| Price Chg. % | 0.00% |
| Open Price | 41.95 |
| High Price | 42.34 |
| Low Price | 41.89 |
| 52w High Price | 46.40 |
| 52w Low Price | 36.50 |
| Volume | 649,202 |
| 30d Avg. Volume | 371,076 |
Products
| Products Manufactured/Services Performed Details |
|---|
Healthcare
|
Biopharmaceuticals
|
Allergies
|
Phase I/Phase II Clinical Stage Products
Products:
|
Upper Respiratory
|
Monoclonal Antibodies
Products:
|
Cardiovascular System
|
Heart Disorders
|
Heart Failure (HF)
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Products:
|
Complications
|
Edema
|
Loop Diuretic Agents
Products:
|
Myocardial Infarction (MI)
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Products:
|
Thrombolytic Agents
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Vascular Disorders
|
Hypertension
|
Loop Diuretic Agents
Products:
|
Stroke
|
Thrombolytic Agents
Products:
|
Thromboembolism
|
Thrombolytic Agents
Products:
|
Dermatology
|
Lesion/Scaling Disorders
|
Chronic Urticaria
|
Monoclonal Antibodies
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Digestive System
|
Gastrointestinal Tract Disorders
|
Gastroesophageal Disorders
|
Nausea/Vomiting
|
Serotonin Receptor Antagonists
Products:
|
Liver Disorders
|
Cirrhosis
|
Complications
|
Edema
|
Loop Diuretic Agents
Products:
|
Hepatitis
|
Hepatitis B
|
Chronic
|
Interferons
Products:
|
Hepatitis C
|
Chronic
|
Interferons
Products:
|
Interferons/Nucleoside Analogs
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Endocrinology/Metabolism
|
Diabetes
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes
|
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 Receptor Agonists)
Products:
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products:
|
Intermediary Metabolism Disorders
|
Gout
|
Gouty Arthritis
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
Hypercholesterolemia
|
Cholesteryl Ester Transfer Protein Inhibitors (CETP)
Products:
|
Parathyroid Gland Disorders
|
Hyperparathyroidism (HPT)
|
Vitamin D Analogs
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Pituitary Gland Disorders
|
Severe Short Stature
|
Growth Hormones
Products:
|
Turner`s Syndrome
|
Growth Hormones
Products:
|
Research/Preclinical Stage Products
Products:
|
Hematology
|
Phase I/Phase II Clinical Stage Products
Products:
|
Red Blood Cell (RBC) Disorders
|
Anemia
|
Recombinant Human Erythropoietins
Products:
|
Serum Factor Disorders
|
Hypercholesterolemia
|
Cholesteryl Ester Transfer Protein Inhibitors (CETP)
Products:
|
Hypocalcemia
|
Vitamin D Analogs
Products:
|
White Blood Cell (WBC) Disorders
|
Neutropenia
|
Colony Stimulating Factors (CSF)
|
Granulocyte (rhG-CSF)
Products:
|
Immunology
|
Autoimmune Disorders
|
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) Associated Vasculitis
|
Monoclonal Antibodies
Products:
|
Arthritis
|
Rheumatoid Arthritis (RA)
|
Immunotherapy
|
Monoclonal Antibodies
Products:
|
Lupus Erythematosus
|
Systemic (SLE)
|
Immunosuppressants
Products:
|
Monoclonal Antibodies
Products:
|
Multiple Sclerosis (MS)
|
Monoclonal Antibodies
Products:
|
Immune Deficiency Disorders
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)
|
Fusion Inhibitors
Products:
|
Protease Inhibitors
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Research/Preclinical Stage Products
Products:
|
Infectious Diseases
|
Bacterial
|
Antibacterial Agents
|
Broad Spectrum
|
Antibiotics
|
Cephalosporin Derivatives
Products:
|
Narrow Spectrum
|
Digestive System
|
Shigellosis
|
Diaminopyrimidines/Sulfonamides
Products:
|
Otolaryngology (Ear/Nose/Throat)
|
Otitis Media
|
Diaminopyrimidines/Sulfonamides
Products:
|
Respiratory System
|
Bronchitis
|
Diaminopyrimidines/Sulfonamides
Products:
|
Urology
|
Urinary Tract Infections (UTI)
|
Antibacterial Agents (Antibiotics)
|
Diaminopyrimidines/Sulfonamides
Products:
|
Mycological (Fungal)
|
Antifungal Agents
|
Broad Spectrum
|
Azoles
|
Triazoles
Products:
|
Narrow Spectrum
|
Respiratory System
|
Pneumocystis Carinii Pneumonia (PCP)
|
Dihydrofolate Reductase Inhibitors/Dihydropteroate Synthetase Inhibitors
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Research/Preclinical Stage Products
Products:
|
Viral
|
DNA Viruses
|
Hepadnavirus
|
Hepatitis B
|
Chronic
|
Interferons
Products:
|
Herpesvirus
|
Cytomegalovirus (CMV)
|
Viral DNA Polymerase Inhibitors
Products:
|
RNA Viruses
|
Flavivirus
|
Hepatitis C
|
Chronic
|
Interferons
Products:
|
Interferons/Nucleoside Analogs
Products:
|
Orthomyxovirus
|
Influenza A
|
Neuraminidase Inhibitors
Products:
|
Influenza B
|
Neuraminidase Inhibitors
Products:
|
Retrovirus
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)
|
Fusion Inhibitors
Products:
|
Protease Inhibitors
Products:
|
Musculoskeletal System
|
Phase I/Phase II Clinical Stage Products
Products:
|
Skeletal Disorders
|
Bone Disorders
|
Osteoporosis
|
Osteoclast Bone Resorption Inhibitors
Products:
|
Selective Estrogen Receptor Modulators (SERM)
Products:
|
Joint Disorders
|
Ankylosing Spondylitis
|
Immunotherapy
|
Monoclonal Antibodies
Products:
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
Gouty Arthritis
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
Osteoarthritis (OA)
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
Rheumatoid Arthritis (RA)
|
Analgesics
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
Immunotherapy
|
Monoclonal Antibodies
Products:
|
Neurology
|
Neurological Disorders
|
Epilepsy
|
Primary Generalized Seizures
|
Absence (Petit Mal)
|
Adjunctive Therapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
Monotherapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
Akinetic Pattern
|
Adjunctive Therapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
Monotherapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
Myoclonic
|
Adjunctive Therapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
Monotherapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
Neuromuscular Disorders
|
Multiple Sclerosis (MS)
|
Monoclonal Antibodies
Products:
|
Parkinson`s Disease (PD)
|
Adjunctive Treatments
|
Dopamine Receptor Agonists
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Psychiatric Disorders
|
Anxiety
|
Generalized Anxiety Disorder (GAD)
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Products:
|
Panic Disorder
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Products:
|
Schizophrenia
|
Glycine Reuptake Inhibitors
Products:
|
Oncology
|
Breast Cancer
|
Localized
|
Monoclonal Antibodies
Products:
|
Metastatic
|
Antimetabolite Agents
|
Pyrimidine Analogs
Products:
|
Monoclonal Antibodies
Products:
|
Dermatology
|
Basal Cell Carcinoma
|
Hedgehog Pathway Inhibitors
Products:
|
Kaposi`s Sarcoma
|
Interferons
Products:
|
Malignant Melanoma
|
Raf Kinase Inhibitors
Products:
|
Digestive System
|
Colon Cancer/Colorectal Cancer
|
Metastatic
|
Antimetabolite Agents
|
Pyrimidine Analogs
Products:
|
Monoclonal Antibodies
Products:
|
Gastric Cancer (Stomach Cancer)
|
Metastatic
|
Monoclonal Antibodies
Products:
|
Hepatic Cancer (Liver Cancer)
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Products:
|
Pancreatic Cancer
|
Metastatic
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Products:
|
Hematology
|
Leukemia (White Blood Cell Cancer)
|
Lymphoid
|
Chronic
|
Hairy Cell
|
Interferons
Products:
|
Lymphocytic (CLL)
|
Monoclonal Antibodies
Products:
|
Myeloid
|
Chronic
|
Myelogenous (CML)
|
Interferons
Products:
|
Lymphoma (Lymphatic Cancer)
|
Non-Hodgkin`s Lymphoma (NHL)
|
Monoclonal Antibodies
Products:
|
Neurology
|
Brain Cancer
|
Glioma
|
Glioblastoma
|
Monoclonal Antibodies
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Research/Preclinical Stage Products
Products:
|
Respiratory System/Thoracic
|
Lung Cancer
|
Non Small Cell Lung Cancer (NSCLC)
|
EGFR-TK Inhibitors/Monoclonal Antibodies
Products:
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Products:
|
Monoclonal Antibodies
Products:
|
Urology
|
Kidney Cancer (Renal Cell Carcinoma)
|
Metastatic
|
Monoclonal Antibodies
Products:
|
Ovarian Cancer
|
Adenocarcinoma
|
Monoclonal Antibodies
Products:
|
Metastatic
|
Monoclonal Antibodies
Products:
|
Ophthalmology
|
Degenerative Disorders
|
Edema
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Products:
|
Macular Degeneration (AMD)
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Products:
|
Retinitis
|
AIDS-Related Cytomegalovirus (CMV) Retinitis
|
Viral DNA Polymerase Inhibitors
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Pain Management
|
Anesthesia
|
General (Systemic)
|
Reversal
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Products:
|
Non-Narcotics
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Decongestants
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Respiratory System
|
Lower Respiratory Tract Disorders (Lung Disorders)
|
Asthma
|
Prophylactic Treatments
|
Monoclonal Antibodies
Products:
|
Cystic Fibrosis (CF)
|
Recombinant Human Deoxyribonuclease I
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Surgery
|
Cardiovascular System
|
Complications
|
Peripheral Arterial Occlusion
|
Thrombolytic Agents
Products:
|
Toxicology
|
Substance Abuse
|
Withdrawal
|
Alcohol
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Products:
|
Transplantation
|
Bone Marrow
|
Complications
|
Cytomegalovirus (CMV) Infections
|
Viral DNA Polymerase Inhibitors
Products:
|
Neutropenia
|
Colony Stimulating Factors (CSF)
|
Granulocyte (rhG-CSF)
Products:
|
Heart
|
Complications
|
Cytomegalovirus (CMV) Infections
|
Viral DNA Polymerase Inhibitors
Products:
|
Rejection Prophylaxis
|
Immunosuppressants
Products:
|
Hepatic (Liver)
|
Complications
|
Cytomegalovirus (CMV) Infections
|
Viral DNA Polymerase Inhibitors
Products:
|
Rejection Prophylaxis
|
Immunosuppressants
Products:
|
Lung
|
Complications
|
Cytomegalovirus (CMV) Infections
|
Viral DNA Polymerase Inhibitors
Products:
|
Pancreas
|
Complications
|
Cytomegalovirus (CMV) Infections
|
Viral DNA Polymerase Inhibitors
Products:
|
Phase I/Phase II Clinical Stage Products
Products:
|
Renal (Kidney)
|
Complications
|
Cytomegalovirus (CMV) Infections
|
Viral DNA Polymerase Inhibitors
Products:
|
Rejection Prophylaxis
|
Immunosuppressants
Products:
|
Monoclonal Antibodies
Products:
|
Urology
|
Phase I/Phase II Clinical Stage Products
Products:
|
Research/Preclinical Stage Products
Products:
|
Urological Disorders
|
Kidney (Renal)
|
Chronic Renal Failure (CRF)
|
Complications
|
Anemia
|
Recombinant Human Erythropoietins
Products:
|
Edema
|
Loop Diuretic Agents
Products:
|
Weight Management
|
Obesity
|
Lipase Inhibitors
Products:
|
Research/Preclinical Stage Products
Products:
|
Wound Management
|
Research/Preclinical Stage Products
Products:
|
Healthcare Services
|
Patient Care
|
Ambulatory/Outpatient
|
Diagnostic
|
Clinical Laboratories
|
Pathology
Products:
|
Specialized
Products:
|
Medical Devices
|
Clinical Diagnostics
|
Chemistry
|
Analyzers
|
Clinical Chemistry
Products:
|
Urinalysis
Products:
|
Home Testing
|
Glucose Testing/Diabetes Monitoring
|
Invasive
|
Continuous Analysis
Products:
|
Random Analysis
Products:
|
Test Strips
Products:
|
Point of Care Testing
|
Critical Care Analysis
|
Analyzers
Products:
|
Test Cartridges
Products:
|
Kits
|
Cardiac
Products:
|
Reagents
|
Calibrators
Products:
|
Controls
Products:
|
Test Kits
|
Genetic/Molecular Diagnostics
|
Disease Diagnosis
|
Infectious Diseases
|
Automated Analyzers
Products:
|
Reagents
|
Bacterial
|
Tuberculosis
Products:
|
Viral
|
Cytomegalovirus
Products:
|
Hepatitis B Virus
Products:
|
Hepatitis C Virus
Products:
|
Human Immunodeficiency Virus (HIV)
Products:
|
Human Papilloma Virus
Products:
|
Influenza (Flu)
Products:
|
West Nile Virus
Products:
|
Oncology
|
Colorectal Cancer/Colon Cancer
Products:
|
Pharmacogenetic
Products:
|
Urinalysis
Products:
|
Hematology/Hemostasis
|
Hematology
|
Analyzers
|
Multiple Parameter
Products:
|
Hemostasis
|
Analyzers
|
Automated
Products:
|
Reagents
|
Test Kits
|
Thrombin/Thromboplastin
Products:
|
Histology
|
Imaging Systems
|
Cytopathology
Products:
|
Processing Equipment
|
Slide Processing
Products:
|
Tissue Processing
Products:
|
Reagents
|
Biomolecular Stains
Products:
|
Kits
|
DNA Probes
Products:
|
In-Situ Hybridization (ISH)
Products:
|
Preparation/Preservation
Products:
|
Immunoassays
|
Analyzers
|
Accessories
Products:
|
Multiple Assay
Products:
|
Reagents
|
Calibrators
Products:
|
Controls
Products:
|
Test Kits
|
Cardiovascular System
|
Cardiac
Products:
|
Infectious Diseases
|
Bacterial
Products:
|
Viral
Products:
|
Oncology
|
Breast Cancer
Products:
|
Cervical Cancer
Products:
|
Digestive System Cancer
Products:
|
Multiple Tumor
Products:
|
Opthalmology
Products:
|
Toxicology/Drugs Of Abuse
|
Drugs Of Abuse
Products:
|
Therapeutic Drugs
Products:
|
Specimen Collection
|
Blood
|
Capillary
|
Lancets
Products:
|
Drug Delivery
|
Infusion Therapy
|
Delivery Systems
|
Insulin
|
Pumps
|
External/Random Analysis Monitoring System
Products:
|
Implanted
Products:
|
Outsourced Biomedical Services
|
Analytical Services
Products:
|
Bioanalytical Services
|
Nucleic Acid Sequencing
Products:
|
Nucleic Acid Synthesis
Products:
|
Drug Discovery Services
|
Lead Discovery/Validation/Optimization
|
Assay Development
Products:
|
High Throughput Screening (HTS)
Products:
|
Lead Biologics
|
Antibodies
Products:
|
Target Discovery/Validation
|
Databases
|
Genomics
|
Human
Products:
|
Services
Products:
|
Scientific Products
|
Analytical Instruments
|
Automation/Processing Equipment
|
Automation Equipment
|
Robotic Instruments
|
Workstations
Products:
|
Bioanalytical Instruments
|
Bioanalytical Consumables
|
Cell Biology
|
Cell Culture
|
Cell Lines
Products:
|
Hybridomas
Products:
|
Media
Products:
|
Reagents
|
Lymphokines/Cytokines
Products:
|
Stains/Dyes
Products:
|
Immunology
|
Kits
|
Enzyme-Linked Immunoabsorbent Assay (ELISA)
Products:
|
Reagents
|
Proteins
|
Antibodies
Products:
|
Cytokines
Products:
|
Enzymes
Products:
|
Molecular Biology
|
Electrochemiluminescence (ECL)
|
Reagents
Products:
|
Nucleic Acid Analysis
|
Automated Nucleic Acid Purification Systems
Products:
|
Kits
|
Nucleic Acid
|
Sequencing
Products:
|
Transfection
Products:
|
Polymerase Chain Reaction (PCR)
|
Amplification
Products:
|
Detection
Products:
|
Purification
Products:
|
Reagents
|
Nucleic Acids
Products:
|
Protein Analysis
|
Kits
|
Detection
Products:
|
Expression
Products:
|
Biomolecular
|
Microarray Technology
|
Consumables
Products:
|
Microplate Readers
|
Accessories
Products:
|
Systems
|
Multiple Parameter
Products:
|
Single Parameter
|
Electrochemiluminescence (ECL)
Products:
|
Sequencers
|
Automated
|
Nucleic Acid
Products:
|
Synthesizers
|
Deoxyribonucleic Acid (DNA)/Oligonucleotides
Products:
|
Peptides
Products:
|
Thermal Cyclers
|
Accessories
Products:
|
Systems
Products:
|
Cellular
|
Flow Cytometers
|
Systems
Products:
|
Technology
|
Information Technology (IT) Services
|
Enterprise and Technology Consulting
|
Industry-Specific IT Services
|
Healthcare
Products:
|
Software
|
Industry-Specific
|
Healthcare/Pharma
|
Business Management/Information Systems
|
Patient Data Management
|
Medical Image/PACS Management
Products:
|
Drug Development
|
Molecular Biology
|
General Imaging
Products:
|
Key Financials
| Period Length/End |
6 months ending 12/31/2011 |
3 months ending 09/30/2011 |
6 months ending 12/31/2010 |
12 months ending 12/31/2011 |
12 months ending 12/31/2010 |
12 months ending 12/31/2009 |
| Total Revenue | 20,860.0 | 9,821.0 | 23,863.1 | 42,531.0 | 49,606.1 | 51,255.0 |
Gross Margin %
|
71.98 | 100 | 71.87 | 71.92 | 72 | 70.2 |
Operating Income
|
5,994.0 | 9,821.0 | 5,223.6 | 13,454.0 | 14,072.1 | 12,806.7 |
Operating Margin %
|
28.73 | 100 | 21.89 | 31.63 | 28.37 | 24.99 |
| Tax Rate % | 17.86 | n/a | 15.56 | 19.7 | 20.69 | 16.83 |
| Income After Taxes | 4,285.0 | n/a | 3,475.4 | 9,544.0 | 9,290.5 | 8,892.4 |
| Net Income Margin % | 20.54 | n/a | 14.56 | 22.44 | 18.73 | 17.35 |
F.D. EPS - Incl. Xord. Items
|
4.94 | n/a | 0.98 | 10.98 | 2.64 | 2.36 |
| Book Value Per Share | 14.02 | n/a | 2.87 | 14.02 | 2.87 | 2.23 |
Ratios
P/R Ratio (TTM)
|
2.12 |
P/E Ratio (TTM)
|
25.19 |
| Price To Free Cash Flow (TTM) | n/a |
| Price To Book Value | 12.19 |
| Net Assets to Market Cap. % | 33.50% |
| Beta | 0.51 |
Days to Sell Inventory
|
315.17 |
Current Ratio
|
1.74 |
Quick Ratio
|
1.3 |
| Interest Coverage | n/a |
| Debt to Market Cap. % | 16.17% |
| Return on Equity % | 354.76 |
| Return on Assets % | 69.68 |
| Return on Invested Capital % | 296.71 |
Major Competitors
| Name | Trailing Revenue | P/R Ratio (TTM) | P/E Ratio (TTM) | 1 Year Return % | Overlap |
|---|---|---|---|---|---|
Abbott Laboratories
|
39,267.0 | 2.46 | 18.80 | 16.95% | 55 |
Amgen Inc
|
15,924.0 | 4.11 | 17.61 | 20.25% | 16 |
Astellas Pharma Inc
|
969,387.0 | n/a | n/a | 5.65% | 17 |
Astrazeneca PLC
|
32,648.0 | 1.79 | 7.02 | -16.27% | 24 |
Bayer AG
|
41,014.6 | 1.37 | 17.89 | -17.74% | 20 |
Becton Dickinson & Co.
|
7,943.3 | 2.10 | 14.50 | -12.84% | 25 |
Bristol Myers Squibb Co
|
21,484.0 | 2.63 | 14.84 | 15.13% | 28 |
Eli Lilly & Co
|
24,049.3 | 1.99 | 11.08 | 7.78% | 23 |
GlaxoSmithKline PLC
|
31,752.9 | 3.65 | 15.41 | 5.77% | 39 |
Johnson & Johnson
|
113,395.0 | 1.55 | 10.12 | -3.35% | 48 |
Merck & Co Inc
|
48,198.0 | 2.43 | 16.89 | 3.82% | 43 |
Novartis SA
|
59,066.0 | 2.47 | 16.87 | -11.66% | 73 |
Pfizer Inc
|
99,814.0 | 1.77 | 12.80 | 9.90% | 43 |
Sanofi
|
42,784.1 | 2.27 | 19.01 | -5.80% | 42 |
Takeda Yakuhin Kogyo KK
|
1,508,932.1 | n/a | n/a | -14.29% | 7 |
| Average | 203,710.6 | 2.35 | 14.83 | 0.22% | 34 |
Notes:
- The company is a pharmaceuticals and diagnostics company. It competes with other biopharmaceutical and healthcare companies, research institutions and universities that are engaged in pharmaceuticals and diagnostics research and development.
Customers
| Name | Last Quarter Financial Stats | 1 YR Price Performance % | |||
|---|---|---|---|---|---|
| Y/Y Revenue Growth % | Sequential Revenue Growth % | Y/Y Margin Growth % | Sequential Margin Growth % | ||
Chugai Seiyaku KK
|
5.29 | -7.43 | 65.78 | 14.39 | 0.00% |
Lonza Group AG
|
10.14 | 25.65 | 49.33 | -26.85 | -51.52% |
Novartis SA
|
-2.17 | -7.22 | -15.57 | 130.38 | -11.66% |
Orasure Technologies Inc
|
20.27 | -11.59 | -18.94 | -1,375.34 | 30.46% |
TeaRx Ltd
|
n/a | n/a | n/a | n/a | n/a |
Zenyaku Kogyo Co., Ltd.
|
n/a | n/a | n/a | n/a | n/a |
| Average | 8.38 | -0.15 | 20.15 | -314.35 | -8.18% |
Notes:
- The company is a pharmaceuticals and diagnostics company. Its customers include doctors, laboratories, physicians, pathologists, mediacl/pharmaceutical distributors, health organizations and patients. No single customer accounted for 10% or more of the company's total revenues for the fiscal year ended December 31, 2011.
Strategic Partners
| Name | Partnership Types | 1 YR Price Performance % |
|---|---|---|
AC Immune SA
|
In-licensing, Research Collaboration, Supplier | n/a |
Abbott Laboratories
|
Research Collaboration | 16.95% |
Amgen Inc
|
Research Collaboration | 20.25% |
Array Biopharma Inc
|
In-licensing, Research Collaboration, Supplier | 24.73% |
Astellas Pharma Inc
|
In-licensing, Research Collaboration, Supplier | 5.65% |
Astrazeneca PLC
|
In-licensing, Supplier | -16.27% |
BioInvent International AB
|
Research Collaboration | -44.47% |
Biogen IDEC Inc
|
In-licensing, Research Collaboration, Supplier | 41.54% |
Bristol Myers Squibb Co
|
Research Collaboration | 15.13% |
Chugai Seiyaku KK
|
Equity Investment, Research Collaboration | 0.00% |
Clovis Oncology Inc
|
Research Collaboration | n/a |
Curis Inc
|
In-licensing, Research Collaboration, Supplier | 34.60% |
DAIICHI SANKYO CO LTD
|
In-licensing, Research Collaboration, Supplier | n/a |
DNA Electronics Ltd
|
In-licensing, Research Collaboration, Supplier | n/a |
Exelixis Inc
|
Research Collaboration | -53.00% |
Genmab A/S
|
Research Collaboration | -51.56% |
Gilead Sciences Inc
|
Research Collaboration | 27.15% |
GlaxoSmithKline PLC
|
In-licensing, Research Collaboration, Supplier | 5.77% |
Halozyme Therapeutics Inc
|
In-licensing, Research Collaboration, Supplier | 10.19% |
Immunogen Inc
|
In-licensing, Research Collaboration, Supplier | 3.57% |
International Business Machines Corp IBM
|
Research Collaboration | 18.68% |
Life Technologies Corp
|
Out-licensing | -21.83% |
Lonza Group AG
|
Distribution | -51.52% |
Merck & Co Inc
|
In-licensing, Supplier | 3.82% |
Morphosys AG
|
In-licensing, Research Collaboration, Supplier | 0.00% |
Nihon Tobacco Sangyo KK
|
In-licensing, Research Collaboration | 37.52% |
NovImmune SA
|
In-licensing, Research Collaboration, Supplier | n/a |
Novartis SA
|
In-licensing, Out-licensing, Supplier | -11.66% |
Orasure Technologies Inc
|
Out-licensing | 30.46% |
PerkinElmer Inc
|
Research Collaboration | -3.52% |
Seattle Genetics Inc
|
Research Collaboration | 12.27% |
Spirogen Ltd.
|
In-licensing, Research Collaboration, Supplier | n/a |
ThromboGenics NV
|
In-licensing, Research Collaboration, Supplier | 12.24% |
Transgene SA
|
Research Collaboration | -48.56% |
Zenyaku Kogyo Co., Ltd.
|
Out-licensing | n/a |
Abbott Laboratories